非透析依赖CKD患者早期与延迟贫血治疗结局比较
本回顾性队列研究利用日本两个数据库,比较非透析依赖CKD贫血患者启动长效ESA时血红蛋白≥9.0 g/dl(早期)与<9.0 g/dl(延迟)的结局。倾向评分匹配后,延迟治疗与肾脏复合结局风险无关,但心血管复合结局、心衰和全因死亡风险更高,提示血红蛋白低于9.0 g/dl前早期干预的重要性。
要点
- 延迟贫血治疗(Hb<9.0 g/dl启动ESA)不增加肾脏复合结局风险。
- 延迟治疗与更高的心血管复合结局、心衰和全因死亡风险相关。
- 建议在血红蛋白降至9.0 g/dl前启动贫血治疗。
核心结论
- 延迟贫血治疗未增加非透析依赖CKD患者的肾脏事件风险,但增加心血管事件和全因死亡风险。
研究设计与样本
- 回顾性队列研究,使用日本MDV和RWD两个数据库,纳入启动长效ESA治疗的非透析依赖CKD贫血患者,按血红蛋白≥9.0 g/dl(早期)或<9.0 g/dl(延迟)分组,经倾向评分匹配后MDV组1472例、RWD组1264例。
主要发现
- 延迟治疗与肾脏复合结局风险无关(MDV:HR 1.15,95%CI 0.99-1.33;RWD:HR 1.08,95%CI 0.92-1.28)。
- 延迟治疗与心血管复合结局风险升高相关(MDV:HR 1.47,95%CI 1.16-1.84;RWD:HR 1.34,95%CI 1.09-1.64)。
- 延迟治疗与心衰风险升高相关(MDV:HR 1.50,95%CI 1.13-2.00;RWD:HR 1.53,95%CI 1.20-1.96)。
- 延迟治疗与全因死亡风险升高相关(MDV:HR 1.83,95%CI 1.32-2.54;RWD:HR 1.64,95%CI 1.21-2.22)。
临床怎么用
- 对非透析依赖CKD贫血患者,可考虑在血红蛋白降至9.0 g/dl前启动长效ESA治疗以降低心血管事件和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The association of hemoglobin level at treatment initiation with renal and cardiovascular outcomes in patients with anemia in nondialysis-dependent (NDD) chronic kidney disease (CKD) is unclear. METHODS: This retrospective cohort study utilized 2 Japanese databases (Medical Data Vision Co. Ltd., Tokyo, Japan [MDV]; and Real World Data Co. Ltd, Kyoto, Japan [RWD]). Patients initiated on long-acting erythropoiesis-stimulating agent (ESA) treatment were divided into early (hemoglobin levels ≥9.0 g/dl) and delayed (<9.0 g/dl) treatment groups. The primary outcome was a renal composite (renal replacement therapy, ≥50% estimated glomerular filtration rate [eGFR] reduction, eGFR <6.0 ml/min per 1.73 m2, and all-cause mortality), and secondary outcomes were a cardiovascular composite (hospitalization by ischemic heart disease, including myocardial infarction, hospitalization by stroke and heart failure, and cardiovascular death) and components of the composite outcomes. RESULTS: After propensity score matching, 1472 (MDV) and 1264 (RWD) patients were evaluated. Delayed treatment was not associated with a risk of the renal composite outcome (MDV: hazard ratio [HR]: 1.15, 95% confidence interval [CI]: 0.99-1.33; RWD: HR: 1.08, 95% CI: 0.92-1.28). However, delayed treatment was associated with higher risks of the cardiovascular composite outcome (MDV: HR: 1.47, 95% CI: 1.16-1.84; RWD: HR: 1.34, 95% CI: 1.09-1.64), heart failure (MDV: HR: 1.50, 95% CI: 1.13-2.00; RWD: HR: 1.53, 95% CI: 1.20-1.96) and all-cause mortality (MDV: HR: 1.83, 95% CI: 1.32-2.54; RWD: HR: 1.64, 95% CI: 1.21-2.22). CONCLUSION: Although the risk of renal events was not increased following delayed treatment of anemia in patients with NDD-CKD, the risks of cardiovascular events and all-cause mortality were increased, suggesting the importance of early intervention before hemoglobin falls below 9.0 g/dl.
引用
- Kawai K, Ishii M, Kokado Y, et al. Outcomes of Early Versus Delayed Anemia Treatment in Nondialysis-Dependent CKD. Kidney Int Rep. 2024. PMID: 39081766. doi:10.1016/j.ekir.2024.04.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。